Changzhou Fangyuan Pharma of Jiangsu Province has completed pre-clinical development work on a difficult-to-produce antibiotic that is effective against methicillin-resistant and gram-negative infections. Arbekacin sulfite was first approved in Japan in 1990, but has now become a generic. Fangyuan plans to file to start clinical trials of arbekacin sulfite in China. Fangyuan said it was helped by the Chinese Academy of Engineering Wang Guangji Academic Workstation, which was set up on Fungyuan’s premises.
